Gaining trust through transparency: the EMERGENT-2 trial - Authors' reply
Lancet
.
2024 Aug 10;404(10452):524.
doi: 10.1016/S0140-6736(24)01269-8.
Authors
Inder Kaul
1
,
Alan Breier
2
,
Andrew C Miller
1
,
Steven M Paul
3
,
Stephen K Brannan
1
Affiliations
1
Karuna Therapeutics, a Bristol Myers Squibb company, Princeton, NJ 08540, USA.
2
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
3
Karuna Therapeutics, a Bristol Myers Squibb company, Princeton, NJ 08540, USA. Electronic address: smpaulmd@gmail.com.
PMID:
39127476
DOI:
10.1016/S0140-6736(24)01269-8
No abstract available
Publication types
Letter
MeSH terms
Clinical Trials as Topic / ethics
Humans
Trust*